Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
188.86
+0.29 (+0.15%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
68
69
Next >
AbbVie Stock Shows Improved Relative Price Strength
April 13, 2023
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see.
Via
Investor's Business Daily
Why Next Week's Earnings Report is Good for Johnson & Johnson
April 13, 2023
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Check Out What Whales Are Doing With ABBV
April 12, 2023
Via
Benzinga
Why 2023 Could Be a Tough Year for AbbVie Stock
April 12, 2023
Should you buy the stock despite its headwinds?
Via
The Motley Fool
2 Forever Stocks to Buy No Matter What the Market Is Doing
April 11, 2023
These two top stocks are trading at very reasonable prices right now.
Via
The Motley Fool
5 High-Yield Dividend Stocks in Warren Buffett's Secret Portfolio You Can Buy Right Now
April 10, 2023
The dividend yields for these Buffett stocks range from 3.7% to 10.6%.
Via
The Motley Fool
The Latest Analyst Ratings for AbbVie
April 05, 2023
Via
Benzinga
This Is What Whales Are Betting On AbbVie
April 03, 2023
Via
Benzinga
AbbVie Unusual Options Activity
March 29, 2023
Via
Benzinga
This Is the Best Dividend ETF You Can Buy
March 28, 2023
ETFs provide stability and diversification to a portfolio.
Via
The Motley Fool
AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades'
April 06, 2023
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with AbbVie Inc. (NYSE: ABBV), which has a 7.3% free cash flow yiel
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
April 05, 2023
Via
Benzinga
Better Dividend Stock: AbbVie vs. Johnson & Johnson
April 05, 2023
Both companies have a lot to offer income-seekers.
Via
The Motley Fool
Want to Collect Big Dividends Each Month? Buy These 3 Stocks
April 05, 2023
These stocks could provide your portfolio with a reliable foundation for growing passive income.
Via
The Motley Fool
Better Buy: AbbVie vs. Johnson & Johnson
March 25, 2023
These pharma giants beat the bear market last year.
Via
The Motley Fool
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
April 03, 2023
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Via
Talk Markets
These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year
April 02, 2023
The dividends should increase for several of these stocks.
Via
The Motley Fool
Week In Review: Apollomics Merges With SPAC To Support Candidates Targeting Difficult-To-Treat Cancers
April 01, 2023
Apollomics, Inc., a US-China biopharma, merged with a SPAC to list on the Nasdaq exchange. At the merger price of $10/share, Apollomics had a market cap of about $900 million, but the shares have...
Via
Talk Markets
Could This Drug News Lift AbbVie's Stock?
April 01, 2023
Alongside Skyrizi, the immunology medicine is part of AbbVie's bright post-Humira future.
Via
The Motley Fool
The Top Healthcare Stocks to Buy With $100
March 31, 2023
With the right stocks, even a small investment can yield huge returns.
Via
The Motley Fool
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
March 31, 2023
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the...
Via
Benzinga
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
March 31, 2023
This medicine is approved for three indications in the U.S. and is well on its way to another.
Via
The Motley Fool
2 High-Yielding Dividend Investments to Buy for the Long Haul
March 30, 2023
Both of these stocks are Dividend Kings, and their payouts are likely to continue rising in the future.
Via
The Motley Fool
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
March 29, 2023
These stocks look reasonably priced considering their future prospects.
Via
The Motley Fool
Better Growth Stock: AbbVie vs. Pfizer
March 29, 2023
One of the pair will have trouble challenging its recent heights.
Via
The Motley Fool
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
March 28, 2023
Via
Benzinga
2 Relatively Safe Dividend Stocks You Won't Regret Owning
March 28, 2023
They're both ready to continue paying a dividend that grows year after year.
Via
The Motley Fool
Is Big Pharma Coming For Your Cannabis Business?
March 27, 2023
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies...
Via
Benzinga
BioNTech Is Ripe For A Rebound In 2023
March 27, 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
March 25, 2023
It isn't an easy decision to choose the best among this group of dividend stocks.
Via
The Motley Fool
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
68
69
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.